Problems of Radiation Medicine and Radiobiology

L. О. Poluben¹, L. V. Neumerzhytska¹, S. V. Klymenko¹, P. Fraenkel², C. Balk², O. O. Shumeiko³

¹State Institution «National Research Center for Radiation Medicine of the National Academy of Medical
  Sciences of Ukraine», 53 Yuriia Illienka St., Kyiv, 04050, Ukraine
²Bes Israel Dikoness Medical Center, Hematology/Oncology Department, Boston, Massachusetts, USA
³Bogomolets National Medical University, 13 Tarasa Shevchenka Blvd, Kyiv, 01601, Ukraine

MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT

Objective. to determine the frequency of major somatic mutations in the JAK2, MPL and CALR genes in the genome of patients with Ph-negative myeloproliferative neoplasms that occur in individuals who have been exposed to ionizing radiation as a result of the Chornobyl accident.
Materials and methods. Molecular genetic analysis of genomic DNA samples isolated from blood was performed in 90 patients with Ph-negative myeloproliferative neoplasia (MPN) with a history of radiation exposure and 191 patients with spontaneous MPN utilizing allele-specific polymerase chain reaction (PCR).
Results. The presence of major mutations in the genes JAK2, CALR and MPL was revealed in patients with MPN with a history of radiation exposure with a frequency 58.9 % (53 of 90), 12.2 % (11 of 90), and 0 % respectively, and without exposure with frequency 75.4 % (144 of 191), 3.1 % (6 out of 191) and 1.6 % (3 out of 191) respectively. Mutations JAK2 V617F in patients with spontaneous MPN were observed in each clinical form: polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). CALR mutations were detected exclusively in patients with PMF and ET, significantly more often in groups with a radiation exposure history (18.9 % and 33.3 %, vs. 4.2 % and 6.5 %) than without one. At the same time, the occurence of MPL mutations was determined only in patients with spontaneous MPN in 1.6 % of casees. Triple negative mutation status of genes JAK2, MPL and CALR prevailed in the group of patients with MPN with a history of radiation exposure and was 27.8 %, against 16.2 % in patients without radiation exposure (p = 0.05).
Conclusions. Genomic research of patients with Ph-negative MPN revealed features of molecular genetic damage in those patients who were exposed to IR as a result of the Chornobyl accident and those with spontaneous MPN. The data obtained by determining of JAK2, MPL and CALR genes mutational status in the genome of patients with MPN is necessary to expand the understanding of the mechanism of leukogenesis, especially caused by radiation.
Key words: myeloproliferative neoplasia, polycythemia vera, essential thrombocythemia, primary myelofibrosis, JAK2 V617F, MPL and CALR, ionizing radiation.

Problems of Radiation Medicine and Radiobiology.
2020;25:362-373. doi: 10.33145/2304-8336-2020-25-362-373

full text

1. Chekhun VF, Gluzman DF. Ionizing radiation and oncohematological diseases. Kiev: DIA; 2016. 284 p.
2. Klymenko SV, Smida J, Atkinson MJ, Bebeshko VG, Nathrath M, Rosemann M. Allelic imbalances in radiation-associated acute myeloid leukemia. Genes (Basel). 2011;2(2):384-393. doi: 10.3390/genes2020384
3. Mishcheniuk OY, Kostukevich OM, Dmytrenko IV, Sholoyko VV, Prokopenko IM, Martina ZV, et al. Molecular characterization of ph-negative myeloproliferative neoplasms in Ukraine. Exp Oncol. 2013;35(3):202-206.
4. Bazyka D, Gudzenko N, Dyagil I, Trotsiuk N, Gorokh E, Fedorenko Z, et al. Incidence of multiple myeloma among cleanup workers of the Chornobyl accident and their survival. Exp Oncol. 2016;38(4):267-271.
5. Minchenko JM, Dyagil IS, Dmytrenko OO, Dmytrenko IV, Shlaykhtychenko TY, Gavrylenko TI, et al. Role of radiosensitivity and radioresistance genetic markers in hematological and cardiovascular disease in persons exposed after the Chornobyl accident. Probl Radiac Med Radiobiol. 2013;18:220-231.
6. Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016;127(3):325-332. doi: 10.1182/blood-2015-07-661835.
7. Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017;129(24):3227-3236. doi: 10.1182/blood-2017-01-761999.
8. Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15.
9. Furtado LV, Weigelin HC, Elenitoba-Johnson KSJ, Betz BL. Detection of MPL mutations by a novel allele-specific PCR-based strategy. J Mol Diagn. 2013;15(6):810-818. doi: 10.1016/j.jmoldx.2013.07.006.
10. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270. doi: 10.1371/journal.pmed.0030270.
11. Chaligne R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P, et al. New mutations of MPL in primitive myelofibrosis: Only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008;22(8):1557-1566. doi: 10.1038/leu.2008.137.
12. Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproli-ferative neoplasms. Blood. 2017;129(6):667-679. doi: 10.1182/blood-2016-10-695940.
13. Lay M, Mariappan R, Gotlib J, Dietz L, Sebastian S, Schrijver I, et al. Detection of the JAK2 V617F mutation by lightcycler PCR and prove dissociation analysis. J Mol Diagn. 2006;8(3):330-334. doi: 10.2353/jmoldx.2006.050130.
14. Lim K-H, Lin H-C, Chen CG-S, Wang W-T, Chang Y-C, Chiang Y-H, et al. Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis. Clin Chim Acta. 2015;440:133-139.
15. Tefferi P, Guglielmelli DR, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507-2513. doi: 10.1182/blood-2014-05-579136.
16. Kenneth O, Bruce T. Community health screening for JAK2 (V617F) mutation, 2010. Available at: http://www.atsdr.cdc.gov/HAC/pha/CommunityHealthScreeningin PA2010/CommunityHealthScreening Report.pdf. Accessed December 29, 2015.
17. Nielsen C, Bojesen SE, Nordestgaard BG, Kofoed KF, Birgens HS. JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. Haematologica. 2014;99(9):1448-1455. doi:10.3324/haematol. 2014.107631
18. Xu X, Zhang Q, Luo J, Xing S, Li Q, Krantz SB, Fu X, Zhao ZJ. JAK2V617F: prevalence in a large Chinese hospital population. Blood. 2007;109(1):339-342. doi:10.1182/blood-2006-03-00947